Soligenix Yönetim
Yönetim kriter kontrolleri 4/4
Soligenix's CEO is Christopher Schaber, appointed in Aug 2006, has a tenure of 18.25 years. total yearly compensation is $700.49K, comprised of 74.2% salary and 25.8% bonuses, including company stock and options. directly owns 0.017% of the company’s shares, worth $1.46K. The average tenure of the management team and the board of directors is 10.4 years and 15.4 years respectively.
Anahtar bilgiler
Christopher Schaber
İcra Kurulu Başkanı
US$700.5k
Toplam tazminat
CEO maaş yüzdesi | 74.2% |
CEO görev süresi | 18.3yrs |
CEO sahipliği | 0.02% |
Yönetim ortalama görev süresi | 10.4yrs |
Yönetim Kurulu ortalama görev süresi | 15.4yrs |
Son yönetim güncellemeleri
Recent updates
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma
Oct 05U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer
Sep 12Soligenix announces $2.6M FDA grant to further study blood cancer candidate
Sep 06Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Sep 06Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M
Aug 12Soligenix, SERB Pharma team up to develop therapy for ricin poisoning
Jul 25Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Apr 22Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?
Jan 03Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now
Sep 17Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?
Aug 30Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?
May 08What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 16Soligenix inks supply and distribution deal for SGX301 companion light device in cancer
Jan 07Soligenix receives $1.5M grant advancing COVID-19 vaccine development
Dec 28CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$7m |
Mar 31 2024 | n/a | n/a | -US$7m |
Dec 31 2023 | US$700k | US$519k | -US$6m |
Sep 30 2023 | n/a | n/a | -US$8m |
Jun 30 2023 | n/a | n/a | -US$10m |
Mar 31 2023 | n/a | n/a | -US$10m |
Dec 31 2022 | US$711k | US$499k | -US$14m |
Sep 30 2022 | n/a | n/a | -US$15m |
Jun 30 2022 | n/a | n/a | -US$15m |
Mar 31 2022 | n/a | n/a | -US$15m |
Dec 31 2021 | US$687k | US$485k | -US$13m |
Sep 30 2021 | n/a | n/a | -US$13m |
Jun 30 2021 | n/a | n/a | -US$12m |
Mar 31 2021 | n/a | n/a | -US$12m |
Dec 31 2020 | US$944k | US$475k | -US$18m |
Sep 30 2020 | n/a | n/a | -US$15m |
Jun 30 2020 | n/a | n/a | -US$16m |
Mar 31 2020 | n/a | n/a | -US$15m |
Dec 31 2019 | US$688k | US$466k | -US$9m |
Sep 30 2019 | n/a | n/a | -US$10m |
Jun 30 2019 | n/a | n/a | -US$9m |
Mar 31 2019 | n/a | n/a | -US$8m |
Dec 31 2018 | US$619k | US$453k | -US$9m |
Sep 30 2018 | n/a | n/a | -US$8m |
Jun 30 2018 | n/a | n/a | -US$7m |
Mar 31 2018 | n/a | n/a | -US$8m |
Dec 31 2017 | US$674k | US$444k | -US$7m |
Tazminat ve Piyasa: Christopher's total compensation ($USD700.49K) is about average for companies of similar size in the US market ($USD655.65K).
Tazminat ve Kazançlar: Christopher's compensation has been consistent with company performance over the past year.
CEO
Christopher Schaber (58 yo)
18.3yrs
Görev süresi
US$700,485
Tazminat
Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Chairman of the Board of Directors | 18.3yrs | US$700.49k | 0.017% $ 1.5k | |
Senior VP | 5.2yrs | US$354.69k | 0.0020% $ 177.8 | |
Senior VP & Chief Scientific Officer | 9.9yrs | US$387.59k | 0% $ 0 | |
Senior VP & Chief Medical Officer | 10.8yrs | US$249.94k | 0.0015% $ 131.2 |
10.4yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: SNGX's management team is seasoned and experienced (10.4 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Chairman of the Board of Directors | 18.3yrs | US$700.49k | 0.017% $ 1.5k | |
Independent Director | 13.4yrs | US$72.50k | 0.0042% $ 370.6 | |
Independent Director | 15.7yrs | US$77.50k | 0.0014% $ 119.7 | |
Independent Director | 15.1yrs | US$80.00k | 0.00083% $ 73.1 | |
Member of Oral Mucositis Medical Advisory Board | no data | Veri yok | Veri yok | |
Member of Pediatric Crohn's Disease Medical Advisory Board | no data | Veri yok | Veri yok | |
Member of Pediatric Crohn's Disease Medical Advisory Board | no data | Veri yok | Veri yok | |
Member of Pediatric Crohn's Disease Medical Advisory Board | no data | Veri yok | Veri yok | |
Member of Cutaneous T-Cell Lymphoma Medical Advisory Board | no data | Veri yok | Veri yok | |
Member of Oral Mucositis Medical Advisory Board | no data | Veri yok | Veri yok | |
Member of Cutaneous T-Cell Lymphoma Medical Advisory Board | no data | Veri yok | Veri yok | |
Member of Cutaneous T-Cell Lymphoma Medical Advisory Board | no data | Veri yok | Veri yok |
15.4yrs
Ortalama Görev Süresi
69.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SNGX's board of directors are seasoned and experienced ( 15.4 years average tenure).